Eisai’s £8 million UK expansion
pharmafile | June 17, 2013 | News story | Manufacturing and Production | Eisai
Eisai has decided to invest further into its Hertfordshire production plant in the UK towards the creation of an additional packaging facility.
Eisai whose headquarters are in Tokyo, said the Hatfield plant is operated by the company’s UK manufacturing subsidiary, Eisai Manufacturing Ltd.
The Hatfield plant serves as a global supply centre for new products such as antiepileptic agent Fycompa, while also functioning as a production and packaging base for countries in Europe.
The new facility will cover a total floor space of approximately 2,900 sq. metres and will be located adjacent to the currently operating facility. It plans to handle the packaging there of its investigational anticancer agent lenvatinib.
Construction is set to begin in September and should be completed by mid-2014, with launch of operations planned for September that year. Eisai’s investment into the facility will total around £8 million, with the firm forecasting a headcount increase of up to 40 permanent positions over the next five to seven years.
Welcoming the development was David Willetts, UK minister of State for Universities and Science, Department for Business, Innovation and Skills who said: “Eisai’s decision to invest is great news for the UK and reflects the government’s commitment to creating the best environment for life sciences. It will build on the Hatfield site’s manufacturing capability, which I saw when I visited last year, and supports highly skilled jobs.”
Eisai’s president, Haruo Naito added: “This new investment is a vote of confidence in our EMEA [Europe, Middle East and Africa] Hatfield facility. The UK remains competitive as a location for advanced manufacturing and I am delighted that we are now able to expand our global centre for packaging at Hatfield, home to our EMEA sales and marketing, R&D and manufacturing operations.”
Eisai established the European Knowledge Centre (EKC), which integrates the company’s discovery research, clinical development, production, marketing, and European headquarters functions into its Hertfordshire site in 2009 with the aim of expanding its business operations in Europe.
Brett Wells
Related Content
Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)
Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical …
Eisai and EcoNaviSta enter dementia collaboration
Eisai and EcoNaviSta have announced that they have entered into a business alliance agreement, initiating …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …
